Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
Holding RARE?
Track your performance easily

Ultragenyx Pharmaceutical (RARE) Financial Statements

717 Followers

Ultragenyx Pharmaceutical Financial Overview

Ultragenyx Pharmaceutical's market cap is currently ―. The company's EPS TTM is $-7.291; its P/E ratio is -8.02; Ultragenyx Pharmaceutical is scheduled to report earnings on October 29, 2024, and the estimated EPS forecast is $-1.47. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Mar 24Dec 23Sep 23Jun 23
Income Statement-
Total Revenue$ 147.03M$ 108.83M$ 127.39M$ 98.05M$ 46.33M
Gross Profit$ 147.03M$ 108.83M$ 127.39M$ 98.05M$ 108.31M
EBIT$ -130.74M$ -136.85M-$ -159.00M$ -159.10M
EBITDA$ -118.12M$ -131.76M--$ -156.95M
Net Income Common Stockholders$ -131.60M$ -170.68M$ -123.19M$ -120.01M$ -159.83M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 763.82M$ 412.08M$ 577.21M$ 442.09M$ 551.98M
Total Assets$ 1.62B$ 1.31B$ 1.49B$ 1.24B$ 1.31B
Total Debt$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Net Debt$ -763.82M$ -412.08M$ -577.21M$ -442.09M$ -551.98M
Total Liabilities$ 1.19B$ 1.17B$ 1.22B$ 1.21B$ 1.18B
Stockholders Equity$ 432.42M$ 140.26M$ 275.41M$ 31.71M$ 129.03M
Cash Flow-
Free Cash Flow$ -81.47M$ -203.94M--$ -132.60M
Operating Cash Flow$ -76.96M$ -190.73M$ -83.90M$ -117.87M$ -116.16M
Investing Cash Flow$ 60.56M$ 94.44M$ -107.02M$ 64.30M$ 99.42M
Financing Cash Flow$ 384.94M$ -58.00K$ 330.61M$ 25.23M$ 33.01M
Currency in USD

Ultragenyx Pharmaceutical Earnings and Revenue History

Ultragenyx Pharmaceutical Debt to Assets

Ultragenyx Pharmaceutical Cash Flow

Ultragenyx Pharmaceutical Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis